{'fraction_non_alphanumeric': 0.021848739495798318, 'fraction_numerical': 0.020168067226890758, 'mean_word_length': 6.740259740259741, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Characterization of Asialoglycoprotein Receptor (ASGPR) Directed Hepatocellular Delivery Using a Pfizer Developed Targeting Ligand PF‐06853291

Asialoglycoprotein receptor (ASGPR) is a transmembrane protein that plays a critical role in serum glycoprotein homeostasis by mediating the endocytosis and lysosomal degradation of glycoproteins with exposed terminal galactose or N‐acetylgalactosamine. This receptor is highly expressed on hepatocytes while extra‐hepatic expression is minimal making the receptor an ideal candidate for targeted delivery of therapeutics to the liver (D'Souza, 2015).